Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Trial
Official title:
A Randomized, Observer-Blind, Dose-Escalation Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults
VIDO has developed a vaccine called COVAC-2. The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The SWE adjuvant is similar to another adjuvant, MF59, that is found in influenza vaccines and MF59 containing vaccines have been given to millions of people around the world. The vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent severe COVID-19 illness. In animal studies, the immune response generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection. This is a Phase 2, placebo-controlled, observer-blind, age-stratified randomized, multicentre study to test the safety and immunogenicity of a dose level of the COVAC-2 vaccine (25 µg protein) administered twice (4 weeks apart) in generally healthy adults 18+ years of age. Up to 300 participants will be enrolled. For an individual participant, the duration of study will be approximately 12 months from the first vaccination (Day 0).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05543616 -
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04516811 -
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19
|
Phase 3 | |
| Completed |
NCT04334044 -
Treatment of SARS Caused by COVID-19 With Ruxolitinib
|
Phase 1/Phase 2 | |
| Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
| Recruiting |
NCT04466241 -
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT04402879 -
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals
|
N/A | |
| Recruiting |
NCT04661631 -
Surgery and Lung Ultrasound in COVID-19 Infection
|
||
| Completed |
NCT04376476 -
Host-pathogen Interactions During SARS-CoV-2 Infection
|
N/A | |
| Completed |
NCT04375098 -
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04402060 -
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04354779 -
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
|
||
| Recruiting |
NCT04367207 -
African Covid-19 Critical Care Outcomes Study
|
||
| Terminated |
NCT04409873 -
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
|
Phase 2 | |
| Completed |
NCT04602351 -
Communication in ICU During COVID-19
|
||
| Terminated |
NCT04707703 -
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
|
Phase 3 | |
| Active, not recruiting |
NCT04987528 -
Pulmonary Fibrosis During Severe COVID-19 Pneumonia
|
||
| Completed |
NCT04667936 -
Evaluation of Sedation in COVID-19 ARDS
|
||
| Completed |
NCT04423770 -
COVID-19 Related Health and Infection Control Practices Among Dentists
|